Alabama
'Cutting the cable' between CD8+ T and T regulatory cells enhances checkpoint immunotherapy
Checkpoint immunotherapy utilizing PD-1 blockade has become the standard of care for metastatic melanoma. While this treatment is effective in 40 percent of patients, the other 60 percent develop resistance, leading to tumor regrowth. A multidiscipli